Positive Outlook for Takeda Pharmaceutical Co: Buy Rating Supported by Promising Phase 3 Data and Projected Sales for Rusfertide

Analyst Koichi Mamegano of Bank of America Securities maintained a Buy rating on Takeda Pharmaceutical Co (TKPHF – Research Report), retaining the price target of Yen5,500.00.

Koichi Mamegano has given his Buy rating due to a combination of factors related to Takeda Pharmaceutical Co’s promising developments in their treatment for polycythemia vera. The presentation of Phase 3 data for rusfertide, a hepcidin mimetic peptide, showed that it met its primary endpoint by significantly reducing the need for phlebotomies in patients, with 76.9% of patients not requiring phlebotomies between weeks 20 and 32. This result was notably better than the placebo group and was consistent across various subgroups, demonstrating its broad effectiveness.
Moreover, rusfertide showed a significant advantage in maintaining hematocrit control compared to placebo, with a favorable safety profile that reported only minor injection site reactions and no serious safety concerns. The convenience of once-weekly administration and its efficacy at all treatment stages make it an attractive option for clinicians. Takeda’s projection of peak sales reaching $1-2 billion, along with plans for a US marketing approval filing, further supports the positive outlook. These factors, combined with a maintained price objective of 5,500 JPY, underpin Mamegano’s Buy rating for Takeda’s stock.